🔥AUROPHARMA🔥 (NSE) POSITIONAL BUY/SELL CALL FOR JUNE 2021

       AUROPHARMA  TARGET 4 ACHIEVED NOW MORE TO GO....  alert-success

AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd. was incorporated within the year 1986. Its today's share price is 959.25. Its current market capitalization stands at Rs 56206.16 Cr. within the latest quarter, company has reported gross revenue of Rs. 133097.4 Cr and Total Income of Rs.136698.5 Cr. The company's management includes B Adi Reddy, K Nithyananda Reddy, Savita Mahajan, Avnit Bimal Singh, P V Ramprasad Reddy, P Sarath Chandra Reddy, M Madan Mohan Reddy, M Sivakumaran, N Govindarajan, K Ragunathan.

It is listed on the BSE with a BSE Code of 524804 , NSE with an NSE Symbol of AUROPHARMA and ISIN of INE406A01037. It's Registered office is at Plot No. 2,Maitrivihar ,AmeerpetHyderabad-500038, Telangana. Their Registrars are ACC Ltd. It's auditors are BSR & Associates LLP, K Nagaraju & Associates, SR Batliboi & Associates, SR Batliboi & Associates LLP, SR Batliboi & Co

Brief about AUROBINDO PHARMA LTD.

Aurobindo Pharma was founded in 1986 by Mr. P. V. Ramaprasad Reddy and Mr. K. Nityananda Reddy. It started its operation with one unit manufacturing semi synthetic penicillin (SSPs) at Pondicherry.

It has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. the corporate is that the market leader in semi-synthetic penicillin drugs.

It has found out overseas branches/ representative offices located in Ethiopia, Tanzania, Kenya, Uganda, Italy, Ghana, Vietnam, and uk .

Aurobindo Pharma has identified international operations, catering to over 100 countries, as a serious engine of growth and expanding global network of selling and manufacturing operations across countries like China, Brazil, Japan, Netherlands, South Africa , Thailand, UK, USA, Russia, Netherlands and lots of more which can further expand its international reach. Subsidiaries in strategic pharmaceutical markets have positioned it to ride the challenges, powered by the strengths, the brilliance and diligence of its global workforce, stellar diary , ever-growing infrastructure and cost-competitiveness.

Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated drug company . Aurobindo’s five units for APIs and 4 units for formulations are designed for the regulated markets.

Its manufacturing units is approved by USFDA, UKMHRA, WHO, MCC-SA and ANVISA-Brazil

In 2012 Aurobindo Pharma commenced work trip into peptides segment. Aurobindo Pharma Ltd. launched its operations within the Kingdom of Bahrain through a grand event held at Hotel Radisson Blu on Monday, 17th Sep’2012.

In April 2014 Aurobindo Pharma Limited announced the completion of the previously announced acquisition of certain commercial operations in Western Europe from Actavis plc (NYSE: ACT). The agreement to accumulate the Actavis operations was announced in January 2014. within the same year Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million. 

In 2017, Aurobindo Pharma inked a pact to accumulate Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of Rs 135 million. It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.

Products

Formulation- during this segment it manufactures formulation for cardio vascular, central systema nervosum , gastroenterologicals, anti-retrovirals and anti-infectives. it's developed formulations namely Trandolapril, Captopril, Benazepril Hydrochloride, etc.

Active Pharmaceutical Ingredients (API) - Aurobindo’s five units for APIs and 4 units for formulations are designed for the regulated markets.

Organic Intermediates- It manufactures wide selection of organic intermediates namely Desmethyl Azithromycin, Methanamine, Benzimidazole, ECPPA and lots of more.

Awards

In 2011 Aurobindo Pharma received Platinum Certificate of Outstanding Exports Award from Pharmexcil.

FUNDAMENTALS

The Indian healthcare sector is predicted to succeed in US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one among India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, insurance , and medical equipment. The structure of the health care delivery system in India consists of three broad segments: medical care , Secondary care, and Tertiary care.

Primary care is that the first point of contact between the population and therefore the healthcare service providers. for instance , Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).

Secondary care providers inpatient also as outpatient medical services and includes simple surgical procedures. for instance , District level & Mid-sized hospitals.

Tertiary care is that the third level of the health care delivery system within the country. These hospitals are specialized consultative healthcare infrastructure. for instance , Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the general public also as private sectors, in urban also as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s check out Aurobindo Pharma and its performance over the amount of your time .

Operating income ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2,161.73 Cr.

Financial Strength: Health care organizations usually have high debt loads and low equity capital in their record . So, Debt to Equity ratio is vital to research the company’s sustainability. Aurobindo Pharma features a Debt to Equity ratio of 0.29 , which may be a strong indication for the corporate .

EPS growth: Investors should make sure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the corporate . In Aurobindo Pharma , the EPS growth was 22.42 you which of them is sweet for the corporate .

Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a corporation with reference to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 20.24 you which of them may be a good sign for profitability.

ROE: Aurobindo Pharma have a average ROE of 15.37 %. ROE is a crucial financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is employed for generating profits.

TECHNICALS